2-吖丁啶酮,3,3,4-三甲基- | 13423-21-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 中文名称: 2-吖丁啶酮,3,3,4-三甲基-
• 英文名称: 3,3,4-trimethyl-azetidin-2-one
• 英文别名: 4-methyl-3,3-dimethyl-2-azetidinone；3,3,4-Trimethylazetidin-2-one
• CAS: 13423-21-7
• 化学式: C₆H₁₁NO
• 分子量: 113.159
• InChiKey: ORMWGSZRBHUGBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-吖丁啶酮,3,3,4-三甲基- 在 盐酸 、 sodium carbonate 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 42.0h， 生成 Methyl 2-[1-[2,2-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]piperidin-4-yl]acetate
  参考文献：
  名称：

  GPIIb/IIIa Integrin Antagonists with the New Conformational Restriction Unit, Trisubstituted β-Amino Acid Derivatives, and a Substituted Benzamidine Structure

  摘要：

  Ethyl N- [3 -(2-fluoro-4-(thiazolidin-3-yl(imino)methyl)benzoyl)amino-2,2-dimethylpentanoyl]piperidine-4-acetate 40 (NSL-96184:) is a highly potent and orally active fibrinogen receptor antagonist, which is characterized by the presence of the trisubstituted beta-amino acid residue, 3 -ethyl-2,2-dimethyl-beta-alanine. This compound was developed on the basis of the SAR study of N-[3-(N-4-amidinobenzoyl)amino-2,2-dimethyl-3-phenylpropionyl]piperidine-4-acetic acid 1 (NSL-95301) with the derivatization focused on the central trisubstituted beta-amino acid unit as well as the basic amidinobenzoyl unit, and the esterification of the carboxyl group for prodrug composition, Compound 1, which was report;ed in our previous study, was discovered by the application of combinatorial chemistry. The molecular modeling study suggests that the trisubstituted beta-amino acid unit is responsible for fixing the molecule to its active conformation. Compound 40 showed an excellent profile in the in vitro and in vivo studies for its human platelet aggregation inhibitory activity and oral availability in guinea pigs. This oral availability largely depends on the modification of the amidino group with a cyclic secondary amine, i.e., thiazolidine in 40. In in vivo studies, the onset of the antiplatelet action of 40 is very fast after oral administration, whereas its duration of action is relatively short. These results suggest that 40 has an excellent therapeutic potential, especially for antithrombotic treatment in the acute phase. 3-Substituted-2,2-dimethyl-beta-amino acid residues would serve as new and useful linear templates to restrict the conformational flexibility of peptidomimetics.

  DOI：

  10.1021/jm980126v
• 作为产物：
  描述：

  methyl 3-amino-2,2-dimethylbutanoate 在 乙基溴化镁 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以87%的产率得到2-吖丁啶酮,3,3,4-三甲基-
  参考文献：
  名称：

  Electroorganic chemistry. 82. .beta.-Amino acid esters from .alpha.-methoxycarbamates and ketene silyl acetals; cyclization to .beta.-lactams

  摘要：

  DOI：

  10.1021/jo00180a020

文献信息

• Fibrinogen receptor antagonist and pharmaceutical compositions
  申请人：Nippon Steel Corporation

  公开号：US05866592A1

  公开（公告）日：1999-02-02

  Compounds of the following general formula (I) and pharmaceutically acceptable salts thereof.

  以下一般式（I）的化合物及其药用可接受的盐。
• A novel method for generation of enolizable N-trimethylsilylaldimines and application to β-lactam synthesis
  作者：Tadao Uyehara、Ichiro Suzuki、Yoshinori Yamamoto

  DOI：10.1016/s0040-4039(01)80709-7

  日期：1989.1

  A new method to generate N-trimethylsilylaldimines has been developedby the combination of bis(trimethylsilyl)formamide and organolithium reagents and applied successfully to β-lactam synthesis.

  通过双（三甲基甲硅烷基）甲酰胺和有机锂试剂的结合，开发了一种新的生成N-三甲基甲硅烷基亚胺的方法，并成功地应用于β-内酰胺的合成。
• SHONO, TATSUYA;TSUBATA, KENJI;OKINAGA, NOBUYUKI, J. ORG. CHEM., 1984, 49, N 6, 1056-1059
  作者：SHONO, TATSUYA、TSUBATA, KENJI、OKINAGA, NOBUYUKI

  DOI：——

  日期：——
• FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED (b)-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：NIPPON STEEL CORPORATION

  公开号：EP0800516A1

  公开（公告）日：1997-10-15
• US5866592A
  申请人：——

  公开号：US5866592A

  公开（公告）日：1999-02-02